Bio-Path (NASDAQ:BPTH) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the stock.

Separately, Roth Mkm reissued a “buy” rating and issued a $20.00 target price on shares of Bio-Path in a report on Monday, July 8th.

Bio-Path Price Performance

Shares of BPTH stock opened at $0.89 on Friday. Bio-Path has a 1 year low of $0.88 and a 1 year high of $21.60. The firm has a fifty day moving average price of $1.35 and a 200-day moving average price of $2.42.

Bio-Path (NASDAQ:BPTH) last released its quarterly earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.54) by $0.38. During the same period in the prior year, the business posted ($10.60) EPS. Sell-side analysts forecast that Bio-Path will post -6.2 EPS for the current year.

Institutional Investors Weigh In On Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent quarter. 5.74% of the stock is owned by institutional investors and hedge funds.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.